EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern

Javier García-Pérez iD, Mercedes Bermejo iD, Almudena Ramírez-García iD, Humberto Erick De La Torre-Tarazona iD, Almudena Cascajero iD, María Castillo de la Osa iD, Paloma Jiménez, Marta Aparicio Gómez, Esther Calonge iD, Aránzazu Sancho-López, Concepción Payares-Herrera, Rocio Layunta Acero und 5 weitere

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Javier García-Pérez und 16 weiteren Autor:innen. Beteiligte Einrichtung: AIDS Immunopathogenesis Unit, Instituto de Salud Carlos III, Madrid, Spain. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants of concern elicited by vaccination was evaluated in COVID‐19 recovered individuals (Rec) separated 1–3 months (Rec2m) or 4–12 months (Rec9m) postinfection and compared to the response in naïve participants. Antibody‐mediated immune responses were assessed in 66 participants by three commercial immunoassays and a SARS‐CoV‐2 lentiviral‐based pseudovirus neutralization assay. Immunoglobulin (Ig) levels against SARS‐CoV‐2 spike were lower in naïve participants after two doses than in Rec after a single dose ( p < 0.05). After two doses in Rec, levels of total Ig to receptor‐binding domain were significantly increased in Rec9m compared to Rec2m ( p < 0.001). The neutralizing potency observed in Rec9m was consistently higher than in Rec2m against variants of concern (VOCs) Alpha, Beta, Delta, and BA.1 sublineage of Omicron with 2.2–2.8‐fold increases. Increasing the interval between SARS‐CoV‐2 infection and the vaccination with messenger RNA‐based vaccines to more than 3 months generates a more efficient heterologous humoral immune response against VOCs by allowing enough time to mount a strong recall memory B cell response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Humans2019-nCoV Vaccine mRNA-1273SARS-CoV-2mRNA VaccinesBiological AssayVaccinationAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

Omicronhybrid immunitymRNA-1273neutralizing antibodiestiming of vaccination

Substanzen

2019-nCoV Vaccine mRNA-1273mRNA VaccinesAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • AIDS Immunopathogenesis Unit, Instituto de Salud Carlos III, Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
  • Clinical Pharmacology Department, Instituto de Investigación Sanitaria Hospital Puerta de Hierro Segovia de Arana, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Serology Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
  • Prevention of Occupational Risks Department, Instituto de Investigación Sanitaria Hospital Puerta de Hierro Segovia de Arana, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Infectious Diseases Unit, IBIDAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain.

ORCID-Profile: Javier García-Pérez, Mercedes Bermejo, Almudena Ramírez-García, Humberto Erick De La Torre-Tarazona, Almudena Cascajero, María Castillo de la Osa, Esther Calonge, Cristina Avendaño-Solá, José Alcamí, Mayte Pérez-Olmeda, Francisco Díez-Fuertes

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

García-Pérez, J., Bermejo, M., Ramírez-García, A., De La Torre-Tarazona, H. E., Cascajero, A., Castillo de la Osa, M., Jiménez, P., Aparicio Gómez, M., Calonge, E., Sancho-López, A., Payares-Herrera, C., Layunta Acero, R., Vicente-Izquierdo, L., Avendaño-Solá, C., Alcamí, J., Pérez-Olmeda, M., & Díez-Fuertes, F. (2023). Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology. https://doi.org/10.1002/jmv.28679

Vancouver

García-Pérez J, Bermejo M, Ramírez-García A, De La Torre-Tarazona HE, Cascajero A, Castillo de la Osa M, et al. Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern. Journal of Medical Virology. 2023. doi:10.1002/jmv.28679

BibTeX
@article{GarcaPrez2023,
  author = {García-Pérez, Javier and Bermejo, Mercedes and Ramírez-García, Almudena and De La Torre-Tarazona, Humberto Erick and Cascajero, Almudena and Castillo de la Osa, María and Jiménez, Paloma and Aparicio Gómez, Marta and Calonge, Esther and Sancho-López, Aránzazu and Payares-Herrera, Concepción and Layunta Acero, Rocio and Vicente-Izquierdo, Laura and Avendaño-Solá, Cristina and Alcamí, José and Pérez-Olmeda, Mayte and Díez-Fuertes, Francisco},
  title = {Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28679}
}
Kostenlos starten →